CIA
BMRN icon

CSat Investment Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

CSat Investment Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,813
Closed -$138K – 578
2020
Q3 		$138K Buy
1,813
+160
+10% +$16.2K 0.01% 355
2020
Q2 		$204K Buy
1,653
+1,236
+296% +$123K 0.02% 307
2020
Q1 		$35K Buy
417
+52
+14% +$4.48K 0.01% 609
2019
Q4 		$31K Buy
365
+66
+22% +$4.99K 0.01% 682
2019
Q3 		$20K Buy
299
+24
+9% +$1.85K 0.01% 707
2019
Q2 		$24K Buy
+275
New +$23.5K 0.01% 663

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CSat Investment Advisory's BMRN Position: Q4 2020 in Review

CSat Investment Advisory sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 1,813 shares — an estimated $138K sold.

CSat Investment Advisory first reported a position in BMRN in Q2 2019 and held it in 6 quarters. The position peaked at $204K in Q2 2020. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • CSat Investment Advisory reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 1,813 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $138K.
  • CSat Investment Advisory first reported a position in BioMarin Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • CSat Investment Advisory's BioMarin Pharmaceuticals position peaked at $204K in Q2 2020.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.